Mereo BioPharma
MREO
64 hedge funds and large institutions have $71.8M invested in Mereo BioPharma in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 12 closing their positions.
52% more call options, than puts
Call options by funds: $336K | Put options by funds: $221K
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
7% more funds holding
Funds holding: 60 → 64 (+4)
3.71% less ownership
Funds ownership: 15.19% → 11.48% (-3.7%)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
28% less capital invested
Capital invested by funds: $99.6M → $71.8M (-$27.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$1.74M |
| 2 |
CC
Clearline Capital
New York
|
+$1.36M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.36M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$775K |
| 5 |
E
Ergoteles
New York
|
+$410K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.85M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.25M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.33M |
| 4 |
Holocene Advisors
New York
|
-$2.84M |
| 5 |
CC
Commodore Capital
New York
|
-$2.19M |
MREO Hedge Fund Activity: Q2 2022 in Review
64 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2022, worth a combined $71.8M — down 28% from $99.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MREO positions and 12 closed out — a net gain of 6 holders — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $1.74M. The largest seller was OrbiMed, cutting an estimated $5.85M.
- 64 institutional investors held Mereo BioPharma (MREO) as of Q2 2022, up from 60 in Q1 2022.
- Funds reported $71.8M of Mereo BioPharma stock for Q2 2022, down 28% quarter-over-quarter.
- 18 funds opened new Mereo BioPharma positions in Q2 2022 and 12 closed out, a net change of +6 holders.
- The largest Mereo BioPharma buyer in Q2 2022 was Boxer Capital, an estimated $1.74M added.
- The largest Mereo BioPharma seller in Q2 2022 was OrbiMed, an estimated $5.85M sold.
Based on aggregated 13F filings for Q2 2022.